I, (Dr. Tomasz Kostrweski, CSO, CN Bio) recently had the pleasure of attending the 13th World Congress on Alternatives and Animal Use in the Life
Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies
Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins,
Microphysiological systems for mAbs development: how do they address animal limitations?
Welcome to part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs),
Why the FDA animal testing phase-out for monoclonal antibodies?
In a groundbreaking press release on April 10th, 2025, the FDA announced its decision to phase out animal testing requirements for monoclonal
The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches
New modality drugs, or advanced oligonucleotide therapeutics, refer to innovative approaches that go beyond traditional small molecule approaches to
Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability studies: Are their limitations justified?
In the realm of pharmaceutical research, Caco-2 cells have long been heralded as the gold standard for studying intestinal absorption and
User Group Meeting 2024 – Recap
6 Challenges in ADME Drug Development
When developing drugs, we rely heavily on in vitro, in vivo animal and in silico models to predict how the human body will interact with drugs before
How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials
Imagine a world where developing new medicines is faster, cheaper, and less reliant on the use of animals for testing. Novel multi-organ in vitro